Clinical Trial

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

Study acronym: KARMA
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2 diabetes). This special education plan is compared to a general education plan and considers the higher risk of DKA when using medicines like SGLT2 inhibitors.
Trial Details
NCT Number NCT07421518
Lead Sponsor AdventHealth Translational Research Institute
Conditions Type 1 Diabetes, Type 2 Diabetes
Enrollment 75 participants
Start Date 2026-06
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-19